Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir - HCV GT1 or GT3 with or without cirrhosis

Short-duration Treatment With Elbasvir/Grazoprevir and Sofosbuvir for Hepatitis C: A Randomized Trial
Eric Lawitz,1 Fred Poordad,1 Julio A. Gutierrez,1 Jennifer T. Wells,1 Carmen E. Landaverde,1Barbara Evans,2 Anita Howe,2* Hsueh-Cheng Huang,2 Jerry Jing Li,2 Peggy Hwang,2 Frank J.Dutko,2 Michael Robertson,2 Janice Wahl,2 Eliav Barr,2 and Barbara Haber2

This clinical study is the first to examine the treatment of patients infected with HCV GT1 or GT3 with or without cirrhosis with short durations of a novel regimen of EBR/GZR + SOF. Our data confirm that cirrhotic and noncirrhotic patients with HCV GT1 infection can be cured with 6–8 weeks of treatment, and that an 8–12 week regimen of EBR/GZR + SOF is safe and effective in cirrhotic and noncirrhotic patients with HCV GT3 infection, commonly regarded as one of the
most challenging patient populations to treat..

View Article - Download PDF

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/hep.28877